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ABSTRACT 
Over the past 10 years, polyvalent DNAgold nanoparticle (DNAGNP) conjugate has 
been demonstrated as an efficient, universal nanocarrier for drug and gene delivery with 
high uptake by over 50 different types of primary and cancer cell lines. A barrier 
limiting its in vivo effectiveness is limited resistance to nuclease degradation and non
specific interaction with blood serum contents. Herein we show that terminal PEGylation 
of the complementary DNA strand hybridized to a polyvalent DNAGNP conjugate can 
eliminate nonspecific adsorption of serum proteins and greatly increases its resistance 
against DNase I based degradation. The PEGylated DNAGNP conjugate still retains 
high cell uptake property, making it an attractive intracellular delivery nanocarrier for 
DNA binding reagents. We show it can be used for successful intracellular delivery of 
doxorubicin, a widely used clinical cancer chemotherapeutic drug. Moreover, it can be 
used for efficient delivery of some cellmembrane impermeable reagents such as 
propidium iodide (a DNA intercalating fluorescent dye currently limited to the use of 
staining dead cells only) and a diruthenium complex (a DNA groove binder), for 
successful staining of live cells. 
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INTRODUCTION 
The polyvalent oligonucleotidegold nanoparticle (DNAGNP) conjugate, first developed by 
Mirkin et al.
1
, has been demonstrated to be a wonder material for nanotechnology,
1
 biosensing,
28
 
materials science, and medicine over the past two decades.
913
 It exhibited a number of highly 
attractive properties such as low/non cytotoxicity, excellent biocompatibility, good stability in 
high salt biological buffers, improved resistance against nuclease degradation and universally 
high cell uptake via scavenger receptor mediated endocytosis pathways. Such properties made it 
extremely attractive for multimodal bioimaging and drug/gene delivery. For example, the DNA
GNPs have been used for intracellular gene regulation and siRNA delivery,
1417
 displaying 
impressive gene silencing efficiencies which are better than some widely used gene transfection 
reagents (e.g. lipofectmine).
14
 More recently, a RNAGNP conjugate has shown capable of in 
vivo RNAi therapy of brain cancer with a mouse model.
1819
 The DNAGNP system has also 
been exploited for intracellular delivery of small chemotherapeutic drugs.
2024
 We have found 
recently that a pHresponsive (PR) DNA which exhibits highly reversible, pHtriggered 
conformational switch between a fourstranded imotif and a random coil,
2527
 can be combined 
with GNP to develop an effective nanocarrier for doxorubicin (DOX), a widely used clinical 
cancer chemotherapy drug. It allows for effective treatment of cancer at the cellular level.
12
 The 
PRDNAGNP displays numerous features of an “ideal drug nanocarrier” outlined by Langer et 
al.
28
 It can effectively exploit the gradually acidified local pH of the natural endo/lyso somal 
maturation/trafficking process to achieve effective, pHtriggered intracellular drug release.  
Despite significant studies, most of the DNAGNP systems reported so far have been 
based on unmodified DNAs. The inherent strong negativecharge of the DNA phosphate 
backbone can lead to nonspecific interactions with serum proteins, altering their particle size, 
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charge and pharmacokinetic properties.
2930
 This can lead to strong recognition by the reticulo
endothelial system (RES), resulting in rapid removal from blood circulation. As a result, this can 
limit its ability to exploit the enhanced permeation and retention (EPR) effect, a characteristic 
pathological property of cancer tumour,
28
 to achieve tumourtargeted accumulation, and hence 
compromising its therapeutic efficacy in vivo. Additionally, although the stability of DNA 
against nuclease degradation can be improved by ~3 fold after GNP conjugation,
31
 this may still 
not be not good enough to satisfy the challenging in vivo conditions because of the extensive 
exposure to various nucleases. 
To address the problem of serum protein nonspecific adsorption, the Mirkin group has 
used a post treatment of the formed DNAGNP with a thiolated poly(ethylene glycol, PEG). 
Despite of success, a drawback here has been a reduced DNA/RNA loading on the GNP, due to 
competitive displacement of the thiolated nucleic acid strands on the GNP surface by the 
thiolated PEG passivation molecules. As a result, the number of functional DNA/RNA strands 
on each ~14 nm GNP was found to be only ~35,
18
 a considerable reduction from the typical ≥ 
100 strands found for nontreated DNAGNPs.
112
 Herein we report a new PEGylation strategy 
for the DNAGNP via terminal PEGylation of the complementary strand (MC2). The specific 
hybridisation between the PRDNAGNP and MC2(PEG) then completes the carrier PEGylation 
(Figure 1A). An advantage of this strategy over the post thiolated PEG treatment is that it yields 
more functional DNA strands per GNP (ca. 110 v.s. 35), making it potentially a more effective 
drug or gene nanocarrier. We show our PEGylation approach offers complete resistance to 
nonspecific adsorption of serum proteins in cell culture media and provides >10 times higher 
resistance to DNase I mediated enzymatic digestion. Moreover, the PEGylated DNAGNP 
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nanocarrier still retains high cell uptake which can be exploited for efficient delivery of both 
chemotherapeutic drugs (ca. DOX) and some cell membraneimpermeable reagents to live cells. 
 
 
Figure 1. (A) Schematic procedures of our approach to PEGylated DNAGNP drug nanocarriers. 
Thiolated PRDNA (denoted as M1) was first loaded onto a citrate stabilized 14 nm GNP via goldthiol 
selfassembly to form GNPM1, which was then hybridized to complementary MC2 (unmodified, Route 
1) or PEGmodified MC2s (Route 2) to form the GNPM1/MC2(PEG) carriers. (B) Schematic of 
MC2(EG12)3 preparation via the Michael addition between the maleimidemodified threechain 
oligo(ethylene glycol) and the MC2free sulfhydryl group, forming a stable covalently linked 
MC2(EG12)3. 
RESULTS AND DISCUSSION 
Table 1 summarizes the DNA sequences used in this study. EGm represents uniform, 
singlelength oligo(ethylene glycol, EG) containing “m” EG units, while PEGn represents 
poly(ethylene glycol) with mixed length PEGs containing an average number of “n” EG 
repeats. The thiolated pHresponsive (PR) DNA strand (M1) contains an imotif domain 
consisting of 4 stretches of cytosinerich sequences. The imotif domain is separated by a 
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tenconsecutive thymine (T10) linker from the 5’thiol modification to minimise any 
possible nonspecific interactions with the GNP after conjugation.
12
 The MC2 sequence is 
fully complementary to the M1 imotif domain except for two designed mismatches to 
stop it forming a stable Gquadruplex. The mismatches are also used to tune the stability 
of the resulting doublestranded (ds) DNA structure, ensuring the ability to form a stable 
imotif triggered by the acidic pH environment of intracellular compartment and to 
release the intercalated drugs/reagents as described previously.
12
 The GC rich base pairs 
in the M1/MC2 duplex also allow for convenient loading of doxorubicin (DOX), a widely 
used clinical cancer chemotherapeutic drug, via its preferred GC base pair intercalation.
24
   
 
 
Table 1. The DNA abbreviations and their sequences used in this paper. The two designed 
mismatched bases between MC2 and M1 are highlighted in red. 
DNA name Sequence (5’ → 3’) 
M1 (PRDNA) HS(CH2)6-TTT TTT TTT TCC CTA ACC CTA ACC CTA ACC C 
MC2 GTG TTA GGT TTA GGG TTA GGG 
MC2(EG6)  EG6-GTG TTA GGT TTA GGG TTA GGG 
MC2(PEG17) PEG17-GTG TTA GGT TTA GGG TTA GGG 
MC2(EG12)3 (EG12)3- GTG TTA GGT TTA GGG TTA GGG 
EGm: singlelength oligo(ethylene glycol) containing “m” EG repeat. 
PEGn: a mixed length poly(ethylene glycol) with an average number of “n” EG repeats. 
The MC2 modified with a 5’terminal six EG unit, MC2(EG6), is purchased commercially 
from IBA GmbH (Germany). The synthesis and characterisation of the MC2(PEG17), MC2 with 
a 5’terminal modification of PEG with an average of 17 repeat EG units, has been reported in 
our previous publication.
12
 MC2(EG12)3 is synthesised in house by reaction of a 5’thiol modified 
MC2 with a maleimidemodified, branched threechain PEG each containing 12 EG units 
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[(MethylEG12)3EG4Maleimide (TMM)] as shown schematically in Figure 1B. Details of the 
MC2(EG12)3 characterisation are given in the Supporting Information (SI).  
GNPM1 conjugates with the average M1 strand loading per GNP of 60, 85 and 110 
respectively are prepared by incubating citrate stabilised GNP (~14 nm in diameter, see SI, Fig. 
S1) with 100, 200 and 300 molar equivalent of thiolated M1s followed by salt aging as described 
previously.
12
 The resulting GNPM1 conjugates are then hybridized to the MC2, MC2(EG6), 
MC2(PEG17) or MC2(EG12)3 at a fixed M1:MC2 molar ratio of 1:1 in a 2Nmorpholino 
ethanesulfonic acid (MES) buffer (50 mM MES, 150 mM NaCl, pH 7.4) to complete the carrier 
assembly. Effects of the EG (or PEG) chain length and number and the GNP surface M1 density 
on the carrier’s resistance to nonspecific serum protein adsorption and DNase I digestion are 
investigated. 
 
PEGylation eliminates non-specific adsorption of serum proteins on the DNA-GNP carrier 
The size and surface properties of a drug carrier are critical to its stability, pharmacokinetics and 
biodistribution in vivo, which in turn strongly affect its cancer targeting ability and efficacy. For 
effective cancer targeting via the EPR effect, a characteristic pathological condition of many 
solid tumours, an ideal carrier size should be greater than the renal clearance threshold (~8 nm, 
ensuring long blood halftime)
3233
 but smaller than the average gap of leaky blood vessels of 
solid tumours (~100 nm).
28,34
 The carrier should also minimise the capture by fixed macrophages 
in the liver and spleen,
35
 and have the right surface properties to avoid being recognised and 
cleared out of the body during systemic circulation before reaching the target tumour.
3637
 The 
carrier should not interact strongly with blood components to alter its size and surface properties. 
In this regard, PEGylation has been shown to be one of the most effective and widely used 
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strategies.
3839
 PEGylation can provide a flexible, hydrophilic shield to minimise the nonspecific 
uptake and removal by macrophages. Indeed, PEGylation has shown to be effective at resisting 
nonspecific adsorption of biomolecules on both flat and curved nanoparticle (e.g. magnetic 
nanoparticle, quantum dot) surfaces.
4043
 Therefore the hydrodynamic diameters (Dhs) of the 
DNAGNPs (with ~110 M1 strands per GNP) in MES buffer and in Dulbecco's Modified Eagle 
Medium (DMEM) cell culture media with 10% Fetal Bovine Serum (FBS) are measured by 
dynamic light scattering (DLS) and the results are shown in Figure 2. 
 
Figure 2. (A) Comparison of the hydrodynamic diameters (Dhs) of different GNPM1/MC2 systems in 
MES buffer (white bars) and DMEM cell culture media with 10% FBS (grey bars). (B) Schematic 
presentations of the interaction between DNAGNP and serum proteins: positivelycharged serum 
proteins (or protein domains) may electrostatically adsorb to the strongly negativelycharged DNAGNP, 
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leading to a significantly increased Dh. (C) A dense PEG shield on the PEGylated DNAGNP can prevent 
the adsorption of serum proteins, leading to effectively no change of Dh. 
 
The unPEGylated GNPM1/MC2 displays a Dh of 50 ± 4 nm in MES buffer, while those 
with various PEGmodifications, i.e. GNPM1/MC2(EG6), GNPM1/MC2(PEG17) and GNP
M1/MC2(EG12)3, all show larger Dhs of 55 ± 6, 61 ± 8 and 70 ± 5 nm, respectively (Figure 2A). 
Therefore the size of the GNPDNA carrier gradually increases with the increasing number of 
total PEG units grafted to each MC2 strand. This result agrees well with our design that the MC2 
strands hybridize to the GNPM1 to form the GNPM1/MC2 carrier, leaving the terminal PEG 
grafts extending outwards. As a result, the higher the number of the PEG units grafted on each 
MC2 strand the bigger the volume it will occupy, and hence the bigger the overall carrier Dh. 
In serumcontaining media, the Dh of the unPEGylated GNPM1/MC2 is increased 
significantly (by ~ 30 nm) to ~80 nm, indicating significant adsorption of serum proteins onto 
the carrier. This is most likely due to electrostatic adsorption of some positively charged proteins 
(or domains) onto such a strongly negativelycharged nanocarrier (Figure 2B). This result agrees 
well with those of unmodified DNAGNPs reported in earlier literatures.
29,44
 In contrast, the Dhs 
of the PEGylated GNPM1/MC2s (except for GNPM1/MC2(EG6) which shows a small increase 
of ~ 4 nm) in the cell culture media show effectively no changes over those in the MES buffer, 
indicating no nonspecific adsorption of serum proteins onto the PEGylated nanocarriers. This 
result confirms the success of our PEGylation strategy for the DNAGNP system. PEGylation is 
a wellestablished strategy for resisting nonspecific adsorption of biomolecules on surfaces. It 
has been widely used to improve the pharmacokinetic properties and to reduce nonspecific 
uptake for therapeutic biomolecules.
4546
 In those cases, a few strands of relatively long PEGs 
(with molecular weight of ~540 kDa, containing ~110900 PEG units each) are conjugated to 
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each protein to complete the PEGylation. Here we find that ~110 strands of short PEGs (each 
containing 17 PEG units) are sufficient to completely inhibit the nonspecific adsorption of 
proteins on such a large (Dh ~50 nm) and strongly negativelycharged DNAGNP conjugate. 
Presumably because many such short PEGs create a uniform, flexible, neutral, hydrophilic and 
relatively dense shield on the particle outer surface that can sterically limit the access to the 
underneath DNAs by serum proteins to initiate electrostatic adsorption.
4749
 As a result, the sizes 
of the PEGylated DNAGNP carriers, particularly those with a moderate length or branched 
multichain PEGs, show no measurable changes after exposure to the serum containing culture 
media. This result also agrees well with the earlier reports that longer PEG chains and higher 
PEG density can provide greater shielding efficiency.
5053
 
 
PEGylation improves carrier resistance to DNase I digestion  
In addition to resisting nonspecific adsorption, an effective drug nanocarrier should have 
sufficient stability in vivo. This has been a significant challenge for any DNAbased drug carriers 
because of exposure to numerous nucleases under the in vivo environment that can degrade them 
rapidly. It has been reported that a dense DNA packing on the DNAGNP can increase the 
resistance of DNA to nuclease degradation by ~3 fold, primarily through inhibition of nuclease 
activity by the high local salt (counter ion) concentration surrounding the strongly negatively 
charged DNAGNP.
31
 However, the 3fold improvement may still not be enough to satisfy the 
more challenging in vivo conditions. 
To investigate whether our PEGylation strategy can improve the carrier resistance to 
nuclease degradation, the dsDNAGNPs are treated with a DNA digestive enzyme, DNase I 
(Figure 3A). This process is monitored by following a literature protocol,
31
 but using a different 
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signal readout strategy. Here a DNA intercalating dye, YOPRO1, is used instead of a 
covalently attached fluorophore at the end of the complementary strand.
31
 Compared to the 
literature approach, this strategy has several advantages: First, YOPRO1 binds strongly to 
dsDNA by intercalation which is very similar to that of anticancer drug (e.g. DOX) loading. 
Therefore, the stability of dsDNAGNPYOPRO1 against nuclease degradation should mimic 
more closely to that of the dsDNAGNPDOX system. Second, unlike the covalent labelling 
strategy where each DNA strand contains just one fluorophore, multiple YOPRO1 molecules 
can bind to each dsDNA strand, allowing for a stronger fluorescence readout signal. Third, 
unlike DOX which intercalates preferentially to the GC base pairs,
54
 YOPRO1 intercalation 
does not have base pair preference and takes place throughout the whole dsDNA structure.
55
 
Therefore, the YOPRO1 fluorescence intensity change should present a better reflection of the 
whole dsDNA degradation process than relying on terminal labelling or DOX intercalation. And 
finally, free YOPRO1 is effectively nonfluorescent. Its fluorescence intensity is enhanced by 
>1000 fold after dsDNA binding. This property allows for unambiguous differentiation of the 
DNAbound and free YOPRO1 states after DNase I digestion. 
A series of samples containing the M1/MC2 duplex only, and GNPM1/MC2s (with or 
without PEG modification, with ~85 M1 strands per GNP) with identical effective final M1/MC2 
strand concentrations (80 nM) and DNA strand loading per GNP (85) are mixed with YOPRO1 
(400 nM, M1/MC2:YOPRO1 molar ratio = 1:5) for 10 min before DNase I (2 U/L) is 
introduced. The resulting timedependent fluorescence intensity change of YOPRO1 (λEX/λEM: 
491/509 nm) for each sample is monitored and shown in Figure 3C. The fluorescence decreases 
are all normalised by that of the M1/MC2 duplex only (80 nM) with YOPRO1 (400 nM). The 
fluorescence intensity changes within the first 30 min for all samples are approximately linear, 
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hence the slopes of the resulting linear fits are used to quantify their relative enzymatic digestion 
rates (Figure 3D). As shown in Figure 3C, free M1/MC2 duplex is rapidly digested by DNase I. 
The whole digestion process is complete in ~50 min with an initial rate of 3.03 %/min. In 
contrast, degradation of the GNPM1/MC2 is much slower, with an initial rate of 1.13 %/min, 
~1/3 that of the free duplex DNA alone. This result is in excellent agreement with an earlier 
report that the DNA stability against nuclease degradation can be improved by ~3 fold upon 
GNP conjugation.
31
 The improved resistance is assigned to a high local Na
+
 concentration at the 
DNAGNP surface (to balance its strong negative surface charge) that can inhibit the DNase I 
activity.
31 
 
Figure 3. Schematic presentations of the YOPRO1 loaded (A) dsDNA and (B) PEGylated dsDNAGNP 
systems under treatment of DNase I. The dsDNA only system is quickly degraded by DNase 1 but the 
PEGshield on the dsDNAGNP can provide protection against DNase I digestion. (C) Normalised time
dependent fluorescence changes for the YOPRO1 loaded M1/MC2 and GNPM1/MC2 (with or without 
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PEGylation) conjugates after treatment with DNase I. (D) Comparison of initial rate of degradation 
velocities (%/min) over the first 30 min derived from (C). 
 
All of the PEGylated GNPM1/MC2 carriers exhibit a slower degradation rate than the 
unPEGylated GNPM1/MC2. For singlePEG chain modified systems, GNPM1/MC2(EG6) and 
GNPM1/MC2(PEG17), they both show very similar initial degradation rates of ~0.70 %/min, 
which is ~21% that of the M1/MC2 duplex alone. Significantly, the threePEGchain modified 
GNPM1/MC2(EG12)3 exhibits the slowest degradation rate, 0.32 %/min, which is less than half 
that of the singlePEGchain systems and only ~1/10 that of the free M1/MC2 duplex alone. This 
indicates that modification of GNPM1/MC2 with a branched threechain PEG greatly enhances 
its resistance to DNase I mediated enzyme degradation. 
The enhanced resistance of the PEGylated DNAGNPs to DNase I degradation is likely 
to originate from a combined effect of steric hindrance and high local Na
+
 concentration. A 
dense PEG ‘shield’ on the dsDNAGNP outer surface (Figure 3B) can restrict the enzyme access 
to the underneath DNA structure, just like their ability to resist nonspecific adsorption of serum 
proteins observed above.
38,46
 These highly flexible, hydrophilic PEG chains produce a vast 
number of conformations constantly switching from one to another, acting as a “PEG shield” that 
can significantly reduce the possibility of digestive enzymes to reach the underneath objects. 
Meanwhile, the dense negative charge of the DNAs underneath the “PEG shield” still induces a 
high local Na
+
 concentration that can inhibit the activity of any enzymes managed to penetrate 
the “PEG shield”. Therefore, all three PEGylated DNAGNPs exhibit slower enzymatic 
degradation rates than the unPEGylated GNPM1/MC2. The GNPM1/MC2(EG12)3, which has 
a surface PEG density three times as high as the singlechain PEGs, can produce a much denser 
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and hence more effective steric shield to prevent the access of DNase I to the DNA structures, 
leading to the slowest enzymatic degradation rate.
50, 5658
 
A further insight into the resistance to DNase I degradation is obtained by examining the 
effects of the DNA (hence PEG as each MC2 strand is PEGylated) packing density on the GNP 
surface. Figure 4A shows the initial degradation rates of the unPEGylated GNPM1/MC2s with 
M1 strand loadings of 60, 85 and 110 per GNP, respectively (the M1:MC2 molar ratio is always 
maintained at 1:1). It clearly shows that the higher the DNA strand loading per GNP, the slower 
the degradation rate. For example, the initial degradation rate for the conjugate with 110 M1 
strands per GNP (1.02 %/min) is 46% slower than that with 60 strands (1.89 %/min) and ~11% 
slower than that with 85 strands (1.13 %/min). This is consistent with the mechanism that the 
higher the DNA (negative charge) density, the higher the local Na
+
 ion concentration, and hence 
the more effective inhibition of DNase I activity. A similar trend is also observed for the three
PEGchain modified GNPM1/MC2(EG12)3 (Figure 4B). The initial rate of degradation is 
decreased from 0.32 to 0.25 %/min as the DNA strand loading is increased from 85 to 110, a 
reduction of 22%, which is about twice that observed for the nonPEGylated system (~11%). 
This result indicates that the stability of the PEGylated DNAGNP against DNase I digestion can 
be further enhanced by increasing the GNP surface DNA loading. The combined effect of high 
DNA density (hence high local Na
+
 concentration for inhibiting DNase activity) and PEGylation 
(steric restriction of DNase access to underneath DNA structure) makes it more resistance to 
DNase degradation. This result thus provides a useful guidance towards the design of highly 
stable DNAGNP based drug nanocarriers. 
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Figure 4. (A) Comparison of initial degradation rates for M1/MC2 duplex and unPEGylated GNP
M1/MC2s at different DNA loadings per GNP. (B) Timedependent fluorescence intensity changes of the 
GNPM1/MC2(EG12)3 at M1 strand loadings of 85 (black dots) and 110 (red triangles) per GNP. 
 
GNP-M1/MC2(EG12)3 for intracellular delivery of DNA binding reagents 
The excellent resistance of the GNPM1/MC2(EG12)3 against serum protein adsorption and 
DNase I degradation makes it highly attractive for drug delivery. We have previously shown that 
the GNPM1/MC2 can be used for efficient delivery and pHresponsive release of DOX inside 
cancer cells, leading to high cytotoxicity.
12
 Here we report that the GNPM1/MC2(EG12)3 not 
only can deliver DOX (a widely used clinical anticancer drug for treating bladder, breast, 
stomach, lung, ovaries, thyroid, soft tissue sarcoma, multiple myeloma, some leukemias and 
Hodgkin's lymphoma, Figure 5B), but also propidium iodide (PI), a cell membraneimpermeable 
fluorescent dye, to live human cervical cancer cells (HeLa cells). PI is widely used to stain dead 
cells, but not live cells. As shown in Figure 5C, live HeLa cells are clearly stained by PI after 
exposure to PI mixed with the DNAGNP nanocarrier. The DNAGNPs have been previously 
reported to be internalised by cells mainly via the scavenger receptormediated endocytosis 
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route.
30
 As a result, they should be mainly located in intracellular endosomes or lysosomes. 
Transmission electron microscopy (TEM) analysis of HeLa cells after incubation with the GNP
M1/MC2(EG12)3 for 3 h reveals that this is indeed the case. The GNPs are found to be 
exclusively located in endo/lyso somal like intracellular compartments (Figure 5A), suggesting 
that modification of the GNPM1/MC2 with the threechainPEG does not alter its cell uptake 
pathway. Therefore its intracellular delivery mechanism is likely to be as follows: after cell 
uptake, the gradual acidification of the local environment following the natural endosomal 
maturation process (the local pH in late endosome or lysosome can be as low as 4.3)
59
 will 
trigger the formation of intramolecular imotifs, leading to release of the intercalated PI 
molecules into the cytoplasm. The released PI molecules can then diffuse into the nucleus, 
staining live HeLa cells with a strong red fluorescence as shown in Figure 5C.  
Besides the ability of delivering PI molecules to live cells, the GNPM1/MC2(EG12)3 also 
shows significantly higher stability in vitro than the unPEGylated GNPM1/MC2. For example, 
it shows no observable aggregation or change of physical appearance for at least 24 h even after 
exposure to excess free PI or DOX molecules in solution, whereas the unPEGylated GNP
M1/MC2 is found to have aggregated and precipitated out of the solution under such conditions. 
The greatly improved stability of the GNPM1/MC2(EG12)3 is most likely due to the dense 
branched EG chains on its outer surface that can provide a sufficient hydrophilic physical barrier 
to prevent DNAGNP aggregation resulting from the PI/DOX intercalation induced DNA charge 
neutralisation (both PI and DOX molecules are positively charged). In contrast, the un
PEGylated GNPM1/MC2 is mainly stabilised by electrostatic repulsion among such negatively 
charged nanoparticles. It aggregates readily and precipitates out of solution once its negative 
charges are neutralized. 
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Figure 5. (A) A representative TEM image of HeLa cells after incubation with the GNPM1/MC2(EG12)3 
for 3 h at 37 °C, scale bar = 1 µm. (B) Confocal phase contrast (left), fluorescence (middle) and merged 
optical/fluorescence (right) images of HeLa cells after incubation with GNPM1/MC2(EG12)3DOX for 
1.5 h at 37 °C, scale bar = 25 µm. (C) Confocal phase contrast (left), fluorescence (middle) and merged 
optical/fluorescence (right) images of HeLa cells after incubation with GNPM1/MC2(EG12)3PI for 3 h at 
37 °C, scale bar = 25 µm. 
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To demonstrate the general use of the GNPM1/MC2(EG12)3 for intracellular delivery of other 
types of DNA binding agents, we have further employed it to deliver a fluorescent diruthenium 
(II) complex, [(bpy)2Ru(tpphz)Ru(bpy)2]
4+
, denoted as BPY (Figure 6A). Unlike DOX and PI 
molecules which bind to DNA mainly through intercalation, BPY is DNA groove binder.
60 
BPY 
has been shown to be impermeable to live cell membranes and therefore cannot enter cells on its 
own.
60
 This property is further confirmed from our results shown in Figure 6B: 3 h incubation of 
free BPY with HeLa cells produces negligible BPY fluorescence inside the cells, suggesting no 
significant cell uptake. In contrast, incubation of HeLa cells with the BPY mixed with the GNP
M1/MC2(EG12)3 for 3 h yields strong BPY fluorescence inside HeLa cells, suggesting that the 
GNPM1/MC2(EG12)3 can effectively carry the BPY molecules and successfully deliver them 
into live HeLa cells. Together, these results demonstrate that the GNPM1/MC2(EG12)3 reported 
herein has great potential for intracellular delivery of a wide range of DNAintercalating agents. 
Its excellent stability and resistance against nonspecific adsorption and enzymatic degradation, 
together with high cell uptake, should make it an effective nanocarrier for intracellular delivery 
of any DNAbinding/intercalating reagents. Given a large number of drug molecules and metal 
complexes are known to be DNAbinders,
61
 the robust, versatile PEGylated DNAGNP 
nanocarrier reported herein should have broad applications in bioimaging, drug delivery and 
therapeutics, possibly even at the in-vivo level. 
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Figure 6. Delivery of a cellmembrane impermeable diruthenium complex to live cancer cells by using 
the GNPM1/MC2(EG12)3. (A) Chemical structure of the diruthenium(II) complex, BPY. (B) Confocal 
phase contrast (left), fluorescence (middle) and merged optical/fluorescence images (right) of HeLa cells 
after treatment with the BPY for 3 h at 37 °C. (C) Confocal phase contrast (left), fluorescence (middle) 
and merged optical/fluorescence (right) images of HeLa cells after incubation with GNP
M1/MC2(EG12)3BPY for 3 h at 37 °C. 
 
Conclusions 
In summary, we have developed an effective PEGylation approach for polyvalent DNAGNPs 
by terminal PEGylation of the complementary DNA strand. Hybridisation of the PEGylated 
MC2s to the GNPM1 conjugates produces a dense PEG ‘shield’ on the carrier surface that can 
efficiently mask the strong negative charges, providing high resistance to nonspecific adsorption 
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of serum proteins and greatly improved stability against enzymatic degradation. Particularly, the 
threechain PEG modified DNAGNP nanocarrier is completely resistant to nonspecific 
adsorption of serum proteins and displaying >10fold higher stability against DNase I based 
enzymatic digestion over the corresponding dsDNA alone. Its stability may be further improved 
by increasing the PEG length, the number of PEG branches and/or the GNP surface DNA 
density. Importantly, the PEGylated DNAGNP still retains high cell uptake property. It can be 
used as a general, efficient intracellular delivery nanocarrier for a wide range of DNAbinding/ 
intercalating reagents, including those which are cellmembrane impermeable on their own. Such 
stable and highly resistant DNAGNP nanocarriers should have broad applications in bio
imaging, drug delivery and therapeutics. 
 
 
EXPERIMENTAL SECTION 
Materials 
Hydrogen tetrachloroaurate (III) hydrate, 99.9% (metals basis) and 2(Nmorpholino) ethane 
sulfonic acid monohydrate (MES, 98%) were purchased from Alfa Aesar (UK). Trissodium 
citrate (99%), HCl (36%), HNO3 (70%), NaOH, NaCl (99.99%), and doxorubicin hydrochloride 
were purchased from Fisher Scientific UK limited (Milton Keynes, UK). DMEM (Dulbecco’s 
Modified Eagle’s Medium), PBS (phosphate buffered saline), MTT (3(4,5dimethylthiazol2
yl)2,5diphenyl tetrazolium bromide), FBS (Fetal bovine serum ) and PenicillinStreptomycin 
(10,000 units/mL penicillin, 10 mg/mL streptomycin) and anhydrous DMSO (≥ 99.7%) were all 
purchased from SigmaAldrich UK limited (Dorset, UK). High purity deionised water 
(resistance >18.2 MY.cm), purified by an ELGA Purelab classic UVF system, was used for all 
experiments and for making buffers. All buffers were filtered through a Whatman syringe filter 
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(0.20 µm pore size, Whatman Plc.) before use. HPLC purified DNA oligos, MC2, MC2SH and 
MC2(EG6) were purchased commercially from IBA GmbH (Göttingen, Germany). MC2(PEG17) 
was prepared in house and its preparation and characterization details have been described in our 
recent paper.
12
 (MethylEG12)3EG4Maleimide (TMM) was purchased from Thermo Scientific 
(UK). YOPRO1 was purchased from Life Technologies (UK). DNase I (1 U/µL) was 
purchased from Fisher Bio Reagents (Milton Keynes, UK). All chemicals and reagents were 
used as received unless otherwise stated. 
Preparation of gold nanoparticle 
80 mg HAuCl4 was dissolved in 200 mL of ultrapure water. The solution was then transferred to 
a freshlycleaned 250 mL threenecked flask and heated to reflux in an oil bath under magnetic 
stirring. When the solution began to reflux, an aqueous solution of trisodium citrate (228 mg in 
20 mL water) was quickly added and the resulting solution was continuously refluxed. The color 
of the solution changed from yellow to deep red in ~1 min. After refluxing for another 50 min, a 
stable deep red solution was obtained. The heating bath was then removed and the solution was 
allowed to cool to room temperature naturally. The prepared GNP solution was transferred to a 
clean glass container and stored at room temperature. This produced a ~14 nm GNP stock (as 
confirmed by TEM imaging see, Figure S1 in the SI) with a concentration of ca. 15 nM. 
Preparation of MC2(EG12)3 
100 nmol MC2SH was dissolved in 1 mL of freshly filtered (Whatman syringe filter with 0.22 
\m pore size) MES buffer (50 mM MES, 0.15 M NaCl, pH 7.4) to make a 100 M stock. TMM 
was dissolved in anhydrous DMSO to make a TMM stock solution of 40 mM. 0.5 mL of the 
MC2SH stock solution (50 nmol) was then mixed with 50 \L of TMM stock (the molar ratio of 
MC2SH: TMM = 1:40) to ensure high DNA conversion. The resulting solution was allowed to 
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stand overnight at room temperature to form MC2(EG12)3 via Michael addition between the 
DNA thiol group and the maleimide group in TMP (see Figure 1B). 
Both RPHPLC analysis and purification of MC2(EG12)3 were performed on a Gynkotek HPLC 
Instrument at room temperature using a Phenomenex C18 column (4.6 × 250 mm, 5 \m) with 
mobile phase consisting of TEAA buffer (A) and acetonitrile (B). UV absorbance was monitored 
by a Gynkotek (UVD 340S) detector at 260 nm. The solvent gradient used for analysis and 
purification of the MC2(EG12)3 was 1070% (B) over 30 min. The resulting HPLC eluting 
profiles for MC2SH and MC2(EG12)3 were shown in SI, Figures S2 and S3, respectively. The 
fractions containing the purified MC2(EG12)3 were combined, lyophilized and stored at 20 °C 
till use. Its identity was confirmed by Matrixassisted laser desorption/ ionization time of flight 
mass spectrometry (MALDITOF MS) (see SI, Figure S4). 
Preparation of PEGylated DNA-GNPs 
The DNAGNPs were prepared by following our previously established procedures. Briefly, a 
batch of three 2.2 ml GNP stock solutions (15 nM) obtained above were mixed with 33, 66 and 
100 µL of DNA M1 aqueous stock solution (100 M) overnight (GNP:M1 molar ratios = 1:100; 
1:200; 1:300, respectively). The resulting solutions were then saltaged (0.30 M NaCl) overnight. 
The samples were then centrifuged at 14800 rpm for 60 mins to remove any unconjugated free 
DNAs that were remained in the supernatant, yielding the GNPM1 as an oily pellet that could 
be rapidly redispersed in water. The amounts of unbound free DNAs in the clear supernatants 
were determined as 13.2, 38, and 62.7 pmole by monitoring the UV absorption at 260 nm using 
an extinction coefficient of εM1 = 2.65 × 10
5
 cm
1
M
1
. The amounts of DNA conjugated onto the 
GNP were thus determined as 19.8, 28, and 37.3, nmole respectively. Given 0.33 pmole of GNP 
was used for each sample, the M1 strand loading per GNP was thus determined as 60, 85, and 
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110, respectively for the above samples.
12
 Afterwards, the complementary MC2 strands (MC2, 
MC2(EG6), MC2(PEG17) or MC2(EG12)3) were added to the GNPM1 (under a fixed M1:MC2 
molar ratio of 1:1) and were allowed to hybridize in an MES buffer for 1 h to make GNP
M1/MC2, GNPM1/MC2(EG6), GNPM1/MC2(PEG17) and GNPM1/MC2(EG12)3 nanocarriers. 
Dynamic light scattering (DLS) measurement  
The hydrodynamic diameters (Dhs) of the DNAGNPs (with M1 strand loading of 110 per GNP) 
were measured in both MES buffer (pH 7.4) and in complete DMEM media with 10% FBS. 
Briefly, 30 µL of the dsDNAGNP stock solution (0.46 M GNP) was mixed with 1.2 mL of 
MES buffer or complete DMEM, and then filtered through a Whatman syringe filter (0.22 \m 
pore size). After 3 h, their Dhs were measured on a Brookhaven Instruments Corp BI200SM 
Laser Light Scattering Goniometer with a BIAPD detector, using an HeNe laser at 633 nm 
(scattering angle: 90°).
12
 
DNase I digestion Experiments  
The dsDNAGNP samples were mixed with YOPRO1 and then diluted to 200 µL with the 
enzyme working buffer (10 mM TrisHCl, 2.5 mM MgCl2 and 0.5 mM CaCl2, pH 7.5) to give a 
final concentration of 80 nM for the dsDNA and 400 nM for YOPRO1. After 10min 
equilibration at 37 °C, the DNase I was added to yield a final DNase I concentration of 2 U/L. 
The resulting fluorescence intensity change for each sample was measured on a fluorescence 
plate reader every 90 seconds for 3 h (λEX = 491 nm; λEM = 509 nm) and normalized against that 
of YOPRO1 + dsDNA sample. 
GNP-M1/MC2(EG12)3 for PI delivery 
All confocal fluorescence imaging were carried out on a Leica TCS SP5 confocal laser scanning 
microscope with a fixed excitation wavelength of (λEX) of 488 nm. The GNPM1 conjugate was 
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mixed with MC2(EG12)3 (M1: MC2(EG12)3 molar ratio = 1:1) in an MES buffer (pH 7.4), and 
hybridized for 3 h to make a GNPM1/MC2(EG12)3 carrier. The PI stock solution (1 mg/mL in 
water) was then added to form the GNPM1/MC2(EG12)3PI system (M1:PI molar ratio = 1:6). 
10
5
 HeLa cells per well were seeded in a 24well plate, incubated overnight and then treated with 
the GNPM1/MC2(EG12)3PI (containing 10 µM PI) for 3 h. The spent medium was removed, 
and the cells were washed with PBS three times before being imaged on a confocal laser 
scanning microscope, using 488 nm excitation and fluorescence detection over 600630 nm. 
Delivery of DOX 
The DOX stock solution (500 µM) was mixed with GNPM1/MC2(EG12)3 to form the GNP
M1/MC2(EG12)3DOX system (M1:DOX molar ratio = 1:3). 10
5
 HeLa cells per well were 
seeded in a 24well plate, incubated overnight and then treated with the GNPM1/MC2(EG12)3
DOX (containing 5 µM DOX) for 1.5 h. The spent medium was then removed, and the cells 
were washed with PBS three times. They were then imaged on a confocal laser scanning 
microscope using 488 nm excitation and fluorescence detection over 580600 nm. 
Delivery of di-ruthenium(II) complex, BPY 
BPY was dissolved in water and mixed with GNPM1/MC2(EG12)3 to prepare GNPM1/MC2
(EG12)3BPY (the molar ratio of M1 to BPY is 1:9). The HeLa cells treated with GNPM1/MC2
(EG12)3BPY (containing 30 µM BPY) for 3 h. The spent medium was then removed, and the 
cells were washed with PBS three times as above. The cells were then imaged by confocal laser 
scanning microscopy using 488 nm excitation and fluorescence detection over 630670 nm. 
Transmission electron microscopy 
5 × 10
5
 HeLa cells per well were seeded in 6well plates and incubated overnight at 37°C. The 
cells were treated with the GNPM1/MC2(EG)3 nanocarrier in media for 3 h at 37°C. After 
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washing with PBS, the cells were detached and centrifuged. The cell pellets were fixed with 
2.5% glutaraldehyde in 0.1 M phosphate buffer for 2.5 h, dehydrated using an ascending alcohol 
series (20, 40, 60, 80 and 100% twice) for 20 min for each change and embedded in Araldite 
resin at 65°C overnight. A 70 nm section was placed on a TEM grid and stained with saturated 
uranyl acetate and 0.2% Reynolds lead citrate before TEM imaging.
12
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